ASMB - NASDAQ

Assembly Biosciences, Inc.

ASMB·NASDAQ

$24.57

+0.33%

HealthcareBiotechnology

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$390.48M

EPS-0.5500

P/E Ratio-44.67

Earnings Date08/05/2026

257.59M

Assets

116%

3Y+153.0%

5Y-9.0%

10Y+163.0%

50.84M

Total Liabilities

-41%

3Y+166.0%

5Y+19.0%

10Y+179.0%

206.75M

Total Equity

520%

3Y+150.0%

5Y-14.0%

10Y+159.0%

Assembly Biosciences, Inc. Funding & Solvency Profile

ASMB · NASDAQ

Current Assets

Cash & Cash Equivalents58.45M

Net Receivables974.00K

Inventory0.00

Other Current Assets5.47M

Total Current Assets255 M

Non-Current Assets

Property, Plant & Equipment2.73M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets312.00K

Total Non-Current Assets3 M

Total Assets

257.59M

Financial Health Analysis

Current Ratio

5.22x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.25x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

206 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Assembly Biosciences, Inc. Balance Sheet

ASMB • NASDAQ

Assembly Biosciences, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	58.5M	38.3M	19.8M	52.4M	45.6M	59.4M	46.7M	41.5M	82M	28.6M	27.1M	29.1M	27.1M	20.5M	37M	14.6M	81.3K	15.9K
Short-Term Investments	189.7M	73.7M	110.4M	39.2M	101M	157M	227.3M	176.6M	37.9M	24.4M	40.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	248.1M	112.1M	130.2M	91.6M	146.6M	216.4M	274M	218.1M	119.9M	53M	67.7M	29.1M	27.1M	20.5M	37M	14.6M	81.3K	15.9K
Net Receivables	974K	400K	43K	944K	336K	1.2M	3.4M	2.4M	2.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	974K	0.0	43K	944K	336K	1.2M	3.4M	2.4M	2.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	400K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	-3.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	3.2M	4.1M	7.2M	6.9M	5.4M	2M	898K	611.2K	704.3K	0.0	0.0	0.0	0.0	0.0	0.0	800K
Other Current Assets	5.5M	3M	3.5M	300K	0.0	0.0	5.4M	2M	0.0	0.0	0.0	125.3K	63.7K	59.6K	62.1K	18.9K	2.5K	5.2K
Total Current Assets	254.5M	115.5M	133.8M	97M	154.2M	224.5M	282.8M	222.5M	123.1M	53.6M	68.4M	29.2M	27.1M	20.5M	37M	14.6M	83.8K	821K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	2.7M	3.4M	2.7M	3.9M	7.2M	10.7M	13.8M	557K	860K	214.7K	148.6K	156.4K	7.1K	6.8K	8.2K	0.0	12.5K	17.5K
Goodwill	0.0	0.0	0.0	0.0	0.0	12.6M	12.6M	12.6M	12.6M	12.6M	12.6M	12.7M	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	0.0	0.0	0.0	0.0	29M	29M	29M	29M	29M	29M	29M	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	41.6M	41.6M	41.6M	41.6M	41.6M	41.6M	41.7M	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	28M	0.0	-8M	0.0	3.3M	2.4M	23.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	312K	312K	312K	889K	1.7M	6.4M	1.7M	3.3M	339.6K	255.4K	197.2K	115K	0.0	0.0	0.0	26.6K	69.9K	31.9K
Total Non-Current Assets	3M	3.7M	3M	4.8M	36.9M	58.8M	57.1M	45.5M	46.2M	44.5M	65.4M	42M	7.1K	6.8K	8.2K	26.6K	82.4K	49.4K
Total Assets	257.6M	119.2M	136.8M	101.8M	191.1M	283.3M	339.9M	268M	169.3M	98.1M	133.7M	71.2M	27.1M	20.6M	37M	14.6M	166.3K	870.4K
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.2M	585K	461K	2.5M	2.7M	4.6M	1.7M	3.7M	2.1M	2.4M	1.4M	907.6K	2.6M	1.8M	2.3M	312.9K	398.1K	4.1M
Accounts Payable	1.2M	585K	461K	2.5M	2.7M	4.6M	1.7M	3.7M	2.1M	2.4M	1.4M	907.6K	2.6M	1.8M	2.3M	312.9K	398.1K	4.1M
Accrued Expenses	0.0	0.0	5.5M	9.8M	3.8M	9.4M	5.3M	5M	4.5M	4.8M	2M	146.4K	23.4K	898.2K	171K	187.5K	4.1M	417K
Short Term Debt	569K	0.0	0.0	0.0	0.0	0.0	3.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2M	7.8M	170K
Capital Lease Obligations (Current)	0.0	461K	1.2M	3.4M	3.2M	3.4M	3.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	36.9M	37.6M	30.9M	0.0	0.0	0.0	6.4M	5.1M	5.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	10.1M	9.1M	1.1M	599K	6.4M	7M	4.6M	4.7M	6.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Liabilities	48.8M	47.8M	39.2M	16.3M	16.1M	24.4M	24.4M	18.5M	13.5M	7.1M	3.4M	1.1M	2.6M	2.7M	2.5M	1.7M	12.4M	4.7M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3M	1.2M	5.6M
Deferred Revenue (Non-Current)	0.0	0.0	55.4M	0.0	2.7M	9M	30.6M	35.6M	40.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	2.5M	2.5M	3.3M	2.1M	11.1M	11.6M	11.6M	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	35.4M	0.0	2.7M	0.0	0.0	0.0	108K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	2.1M	38M	56.5M	2.8M	6.1M	18.2M	42.3M	38.9M	42.7M	11.1M	11.6M	11.6M	23.4M	898.2M	0.0	1.3M	1.2M	5.6M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-23.4M	-898.2M	0.0	0.0	0.0	0.0
Capital Lease Obligations	2.1M	3.1M	2.3M	3.5M	6.5M	10.1M	12.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	50.8M	85.8M	95.7M	19.1M	22.1M	42.7M	66.7M	57.4M	56.2M	18.2M	15M	12.7M	2.6M	2.7M	2.5M	3M	13.5M	10.3M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-16.6K	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	220.0	0.0	0.0	0.0	0.0	0.0
Common Stock	16K	7K	5K	4K	48K	34K	32K	25K	20.1K	17.2K	17.2K	10.7K	20.7K	12.9K	12.4K	6.7K	447.0	445.0
Additional Paid-In Capital	1B	0.0	826.9M	808M	800.7M	742.4M	712.8M	552.8M	364.5M	288.7M	283.5M	194.1M	135.8M	110.1M	102M	44.8M	4.5M	3.9M
Retained Earnings	-832M	-825.9M	-785.7M	-724.5M	-631.4M	-501.6M	-439.4M	-341.8M	-251M	-208.2M	-164M	-135.5M	-111.7M	-92.3M	-67.5M	-33.2M	-17.9M	-13.4M
Accumulated Other Comprehensive Income/Loss	-41K	-211K	-81K	-803K	-419K	-270K	-201K	-347K	-392.4K	-600.8K	-821.6K	0.0	-39.3K	-33.1K	-28.4K	-27.3K	-14.7K	-7.2K
Other Total Stockholders' Equity	0.0	859.5M	0.0	-1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-16.6K	0.0	0.0	0.0	0.0	7.2K
Total Stockholders' Equity	206.8M	33.4M	41.1M	82.7M	168.9M	240.6M	273.2M	210.7M	113.1M	79.9M	118.7M	58.6M	24.5M	17.8M	34.5M	11.6M	-13.4M	-9.5M
Total Equity	206.8M	33.4M	41.1M	82.7M	168.9M	240.6M	273.2M	210.7M	113.1M	79.9M	118.7M	58.6M	24.5M	17.8M	34.5M	11.6M	-13.4M	-9.5M
SUMMARY
Total Liabilities & Equity	257.6M	119.2M	136.8M	101.8M	191.1M	283.3M	339.9M	268M	169.3M	98.1M	133.7M	71.2M	27.1M	20.6M	37M	14.6M	166.3K	870.4K
Total Investments	189.7M	73.7M	110.4M	39.2M	129M	157M	227.3M	176.6M	41.3M	26.8M	63.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	2.6M	3.1M	2.3M	3.5M	6.5M	10.1M	12.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5M	9M	5.8M
Net Debt	-55.8M	-35.3M	-17.5M	-49M	-39.2M	-49.3M	-34.5M	-41.5M	-82M	-28.6M	-27.1M	-29.1M	-27.1M	-20.5M	-37M	-12.1M	8.9M	5.8M
Shares Outstanding	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157	7,672,157

SEC Filings

ASMB - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 26, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 22, 2026	May 22, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 22, 2026	June 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 30, 2026	March 24, 2026	2026	View Filing
S-3 S-3 N/A	March 19, 2026	March 19, 2026		View Filing
10-K 10-K 2025 FY FY	March 19, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 19, 2026	March 19, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 08, 2025	December 08, 2025	2025	View Filing

Showing 1 to 10 of 291 filings

Related Guides

Blog Categories

Continue your ASMB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.